Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of IFN (Interferon)-lambda3 to preparation of medicine for preventing or treating acquired immunodeficiency syndrome

An AIDS and HIV technology, applied in antiviral agents, pharmaceutical formulations, medical preparations containing active ingredients, etc., can solve the problem of preventing or treating AIDS without type III interferon-3

Inactive Publication Date: 2017-05-31
武汉市疾病预防控制中心
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It is reported in the prior art that type III interferon has the function of regulating NK cells and has a good effect on the treatment of hepatitis, but there is no relevant report about type III interferon-3 (IFN-λ3) in the prevention or treatment of AIDS

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of IFN (Interferon)-lambda3 to preparation of medicine for preventing or treating acquired immunodeficiency syndrome
  • Application of IFN (Interferon)-lambda3 to preparation of medicine for preventing or treating acquired immunodeficiency syndrome

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Using an in vitro model of HIV-infected human macrophages, the activity of HIV reverse transcriptase was quantitatively detected by radioimmunoassay, and it was proved that IFN-λ3 has the activity of inhibiting HIV-infected human macrophages, which was detected by direct immunofluorescence technique Intracellular HIV p24 antigen also demonstrated this activity. The inhibitory effect is related to the dose and duration of IFN-λ3, that is, the larger the dose and the longer the duration, the better the inhibitory effect, and the effect before exposure is better than after exposure. figure 1 It is the effect analysis diagram of IFN-λ3 inhibiting HIV. exist figure 1 In A, human macrophages 4 days after HIV infection were treated with 4 concentrations of IFN-λ3 for 8 days, and the HIV inhibitory effect was positively correlated with the concentration of IFN-λ3, among which 100ng / ml IFN-λ3 had the best inhibitory effect, Up to 80% or more. figure 1 In B, human macrophages ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of IFN (Interferon)-lambda3 to preparation of a medicine for preventing or treating acquired immunodeficiency syndrome and belongs to the technical field of biological pharmacy. The medicine prepared from IFN-lambda3 can be used for effectively inhibiting the activity of human immunodeficiency virus infected human macrophage, the expression of anti-virus genes is induced, and the effect of inhibiting the acquired immunodeficiency syndrome is good.

Description

technical field [0001] The invention relates to the technical field of biopharmaceuticals, in particular to an application of IFN-λ3 in the preparation of drugs for preventing or treating AIDS. Background technique [0002] At present, AIDS is still a global public health problem, the main reason being that there is still no specific medicine to completely cure AIDS and a vaccine that can prevent HIV infection. [0003] Currently, the most commonly used AIDS treatment method in clinical practice is a combination drug method, and the most commonly used first-line treatment drugs are tenofovir (TDF) or zidovudine (AZT) + lamivudine (3TC) + efavirenz ( EFV) or nevirapine (NVP), commonly known as cocktail therapy, although this method can significantly inhibit HIV in patients, it still cannot be completely cured; and it is easy to cause HIV mutation, drug resistance, and has greater side effects on patients. [0004] Interferons, a group of active proteins with multiple functio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/21A61P31/18
CPCA61K38/217
Inventor 刘满清
Owner 武汉市疾病预防控制中心
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com